title: Pyoderma gangrenosum: an updated review.
abstract: Pyoderma gangrenosum is a rare, ulcerative, cutaneous condition. First described in 1930, the pathogenesis of pyoderma gangrenosum remains unknown, but it is probably related to a hyperergic reaction. There are various clinical and histological variants of this disorder. Pyoderma gangrenosum often occurs in association with a systemic disease such as inflammatory bowel disease, rheumatologic disease, paraproteinaemia, or haematological malignancy. The diagnosis, mainly based on the clinical presentation and course, is confirmed through a process of elimination of other causes of cutaneous ulcers. Local treatment may be sufficient for mild disease, while for severe cases, systemic immunosuppressants are the mainstay. Long-term treatment with these agents is often required, but this can expose patients to adverse side-effects.
authors.affiliation: Department of Dermatology, Second University of Naples, Naples, Italy.
authors.forename: E
authors.initials: E
authors.lastname: Ruocco
authors.forename: S
authors.initials: S
authors.lastname: Sangiuliano
authors.forename: A G
authors.initials: AG
authors.lastname: Gravina
authors.forename: A
authors.initials: A
authors.lastname: Miranda
authors.forename: G
authors.initials: G
authors.lastname: Nicoletti
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D003093:Colitis, Ulcerative / Q000175:diagnosis; D003424:Crohn Disease / Q000175:diagnosis; D003937:Diagnosis, Differential; D006801:Humans; D011379:Prognosis; D017511:Pyoderma Gangrenosum / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology
chemical_list: D000305:Adrenal Cortex Hormones; D000900:Anti-Bacterial Agents